Renalytix Plc (RNLX)

NASDAQ: RNLX · IEX Real-Time Price · USD
0.301
-0.002 (-0.63%)
At close: Jul 19, 2024, 3:58 PM
0.293
-0.009 (-2.86%)
After-hours: Jul 19, 2024, 7:48 PM EDT
-0.63%
Market Cap 26.57M
Revenue (ttm) 2.22M
Net Income (ttm) -37.49M
Shares Out 90.79M
EPS (ttm) -0.78
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 305,160
Open 0.300
Previous Close 0.303
Day's Range 0.292 - 0.313
52-Week Range 0.220 - 3.660
Beta 2.10
Analysts n/a
Price Target n/a
Earnings Date May 15, 2024

About RNLX

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical tr... [Read more]

Sector Healthcare
IPO Date Jul 17, 2020
Employees 102
Stock Exchange NASDAQ
Ticker Symbol RNLX
Full Company Profile

Financial Performance

In 2023, Renalytix's revenue was $3.40 million, an increase of 14.58% compared to the previous year's $2.97 million. Losses were -$45.61 million, 0.73% more than in 2022.

Financial Statements

News

Renalytix and Steno Diabetes Center Announce Precision Medicine Collaboration Marking First Expansion for KidneyIntelX Platform Beyond US

LONDON and NEW YORK, July 11, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical managem...

9 days ago - GlobeNewsWire

Renalytix Submits Hearing Request to Nasdaq Hearings Panel in Regard to Staff Delisting Determination

Throughout the hearings process and pending the Panel's decision, the Company's ADSs will continue trading on The Nasdaq Global Market under the symbol “RNLX” Throughout the hearings process and pendi...

23 days ago - GlobeNewsWire

Medicare Issues Final Coverage Determination for kidneyintelX.dkd

Company has Achieved Prerequisites for Growing Test Adoption with FDA Authorization, Clinical Outcomes Data, Inclusion in Clinical Guidelines, and Broad Insurance Coverage Company has Achieved Prerequ...

5 weeks ago - GlobeNewsWire

Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2024

LONDON and NEW YORK, May 15, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical manageme...

2 months ago - GlobeNewsWire

Renalytix to Report Financial Results for Third Quarter Fiscal Year 2024 on May 15

LONDON and SALT LAKE CITY, May 09, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that it will report its third quarter fiscal year 2024 financial results on Wednesday, Ma...

2 months ago - GlobeNewsWire

Renalytix Announces Financing with Expected Size of up to $4 Million

LONDON and SALT LAKE CITY, April 08, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces a registered direct offering of ordinary shares at a purchase price equivalent to $0.75...

3 months ago - GlobeNewsWire

KidneyIntelX™ included in Final KDIGO 2024 Clinical Guideline for Chronic Kidney Disease (CKD)

Guidelines highlight the importance of risk prediction and personalized treatment to reduce risk Guidelines highlight the importance of risk prediction and personalized treatment to reduce risk

4 months ago - GlobeNewsWire

Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2024

LONDON and SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (the “Company”), an artificial intelligence-enabled in vitro diagnostics company, focused on optim...

5 months ago - GlobeNewsWire

Renalytix to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

LONDON and SALT LAKE CITY, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (the “Company”) today announced that the Company will be participating in the upcoming BTIG MedTec...

5 months ago - GlobeNewsWire

New published data demonstrates KidneyIntelX™ has broad implications for winning war on chronic kidney disease

Electronic health record deployment of KidneyIntelX was associated with clinical actions that slowed progression of chronic kidney disease and improved Type 2 diabetes control in just 12 months

6 months ago - GlobeNewsWire

Renalytix Reports Financial Results for First Quarter of Fiscal Year 2024

LONDON and SALT LAKE CITY, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical m...

8 months ago - GlobeNewsWire

Renalytix to Report Financial Results for First Quarter Fiscal Year 2024 on November 14

LONDON and SALT LAKE CITY, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that it will report its first quarter fiscal year 2024 financial results on Tuesday, Nov...

9 months ago - GlobeNewsWire

US Patent Office Allows Patent Claims for Intellectual Property Exclusively Licensed to Renalytix

LONDON and SALT LAKE CITY, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), the first company to commercialize an FDA authorized artificial intelligence (AI) enabled blood t...

10 months ago - GlobeNewsWire

Renalytix Reports Full Year Fiscal 2023 Results

LONDON and SALT LAKE CITY, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical ...

10 months ago - GlobeNewsWire

Renalytix to Report Financial Results for Fourth Quarter and Full Year Fiscal 2023 on September 28

LONDON and SALT LAKE CITY, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) will report its fourth quarter and full year fiscal 2023 financial results on Thursday, September...

10 months ago - GlobeNewsWire

Renalytix Appoints Senior Executive Howard Doran as Chief Business Officer

Doran Brings Significant Diagnostics Sector Experience to Lead the KidneyIntelX Global Sales Effort Doran Brings Significant Diagnostics Sector Experience to Lead the KidneyIntelX Global Sales Effort

11 months ago - GlobeNewsWire

Renalytix Clinical Advisory Board Formed to Support Broadening Use of KidneyintelX.dkd

World leading, multi-disciplinary experts advise on adoption of FDA authorized KidneyintelX.dkd across 14 million US patients with diabetes and chronic kidney disease World leading, multi-disciplinary...

1 year ago - GlobeNewsWire

Renalytix Announces Middle East Distribution Agreement with Vector Pharma

Commercial availability of kidneyintelX.dkd™ expanded to an estimated  4 million DKD Patients in the Middle East

1 year ago - GlobeNewsWire

Late-Breaking KidneyIntelX Evidence Released at 83rd American Diabetes Association Scientific Sessions

12 Months KidneyIntelX™ in vitro prognostic testing continued to demonstrate clinical actions that lead to improvement in both diabetes (A1C reductions) and kidney health (eGFR slope improvement) in p...

1 year ago - GlobeNewsWire

Renalytix Appoints Financial Executive Catherine Coste to its Board of Directors

LONDON and SALT LAKE CITY, July 03, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), the first company to commercialize an FDA approved artificial intelligence (AI) enabled prognosti...

1 year ago - GlobeNewsWire

FDA Grants De Novo Marketing Authorization for KidneyIntelX.dkd to Assess Risk of Progressive Kidney Function Decline in Adults with Diabetes and Early-Stage Kidney Disease

Simple Blood Test Aids Risk Assessment for Approximately 14 Million Eligible Patients  in the United States

1 year ago - GlobeNewsWire

KidneyIntelX™ Clinical Decision Impact / Validation and Health Economic Data to be Presented at Upcoming Scientific Conferences

Four new data presentations, including late breaking clinical study data, underscores the value of KidneyIntelX testing in helping slow progression of chronic kidney disease in type 2 diabetes patient...

1 year ago - GlobeNewsWire

Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2023

LONDON and SALT LAKE CITY, June 09, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical m...

1 year ago - GlobeNewsWire

Renalytix to Report Third Quarter Fiscal Year 2023 Financial Results on June 9

LONDON and SALT LAKE CITY, June 05, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) will report its third quarter fiscal year 2023 financial results on Friday, June 9, 2023, before m...

1 year ago - GlobeNewsWire

Renalytix selects EVERSANA® to expand commercialization of KidneyIntelX for Early-Stage Kidney Disease Prognosis Detection in Patients with Type 2 Diabetes

Model expected to accelerate deployment of KidneyIntelX across key U.S. regions with high rates of diabetic kidney disease and established insurance coverage Model expected to accelerate deployment of...

1 year ago - GlobeNewsWire